Tour of Scotland: Edinburgh based Trogenix is developing an AAV based gene therapy platform for cancer that is designed to deliver combination immune payloads to the tumor

CEO Ken Macnamara describes the science behind this idea and discusses recently presented preclinical data. He highlights the lead program for glioblastoma and plans for the future, and also explains how he believes a patient sample biobank Trogenix has built is key to the company's success in research.